NeuroPace (NASDAQ:NPCE – Get Free Report) and Ambu A/S (OTCMKTS:AMBBY – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for NeuroPace and Ambu A/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroPace | 1 | 4 | 5 | 0 | 2.40 |
| Ambu A/S | 0 | 1 | 0 | 0 | 2.00 |
NeuroPace presently has a consensus target price of $15.50, suggesting a potential upside of 105.03%. Given NeuroPace’s stronger consensus rating and higher probable upside, research analysts clearly believe NeuroPace is more favorable than Ambu A/S.
Risk & Volatility
NeuroPace has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Ambu A/S has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Insider & Institutional Ownership
78.8% of NeuroPace shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares NeuroPace and Ambu A/S”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroPace | $99.99 million | 2.59 | -$21.47 million | ($0.57) | -13.26 |
| Ambu A/S | $1.01 billion | 3.11 | $99.84 million | $0.37 | 35.95 |
Ambu A/S has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NeuroPace and Ambu A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroPace | -20.00% | -117.31% | -16.83% |
| Ambu A/S | 9.90% | 10.47% | 8.34% |
Summary
Ambu A/S beats NeuroPace on 8 of the 14 factors compared between the two stocks.
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
About Ambu A/S
Ambu A/S is a Danish medical-device company that develops, manufactures and markets equipment for hospitals and other healthcare settings. Its products are used in anesthesia, patient monitoring and diagnostics, and endoscopy. The company’s portfolio includes ventilation and resuscitation devices, electrodes and single-use endoscopes. Ambu is also known for the Ambu bag, a self-inflating resuscitation bag introduced in the 1950s. Founded in Denmark in 1937, Ambu serves healthcare professionals in markets around the world.
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
